🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "significant breakthrough" in the fight against drug-resistant strains of the infection, according to scientists.

A Global Challenge

Cases of gonorrhoea are on the rise worldwide, with data suggesting over 82 million instances annually. Particularly high rates are seen in Africa and countries within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune advancement in the face of rising global incidence, increasing antimicrobial resistance and the extremely scarce treatment choices currently available.”

Public health authorities are particularly alarmed about the increase in treatment-resistant strains. The World Health Organization has classified it as a "priority pathogen". Ongoing monitoring found that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Receive Clearance

One new antibiotic, also known as Nuzolvence, was cleared by the American regulatory agency in mid-December for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts anticipate that targeted use of this new drug will help delay the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GSK, also received approval in the same week. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a unique collaborative effort for medication research. The charitable organization GARDP collaborated with the drug firm Innoviva to bring it to fruition.

“This authorization represents a huge turning point in the treatment of superbug gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Data and Worldwide Availability

According to findings detailed in a prominent scientific publication, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This places it at an equal footing with the current standard treatment, which uses a dual-drug approach. The trial enrolled hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the ability to make available and distribute the drug in numerous low-income and middle-income countries.

Medical professionals treating patients have shared positive views. Access to a easy-to-administer therapy like this is seen as a "revolutionary step" for gonorrhoea control. This is considered essential to lessen the impact of the disease for individuals and to halt the transmission of highly drug-resistant gonorrhoea around the world.